Results 231 to 240 of about 2,322,151 (276)

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

The engagement equation: a model for understanding what drives voluntary physician engagement with data-driven clinical performance feedback. [PDF]

open access: yesImplement Sci Commun
Desveaux L   +9 more
europepmc   +1 more source

Postmarket Safety Actions for Novel Oncology Drugs Granted FDA's Accelerated Approval.

open access: yesJAMA Netw Open
Mooghali M   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy